Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.

2.50
Hdl Handle:
http://hdl.handle.net/10541/97145
Title:
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.
Authors:
Verweij, J; Judson, I; Steward, William P; Coleman, R; Woll, Penella J; Van Pottelsberghe, C; Van Glabbeke, Martine M; Mouridsen, H
Abstract:
The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with intravenous muramyl tripeptide phosphatidylethanolamine (MTP/PE) at a dose of 4 mg once weekly in 20 patients with metastatic soft tissue sarcomas. Responses were not seen in 19 evaluable patients. Toxicity consisted mainly of a mild flu-like syndrome after 62% of drug administrations. It is concluded that MTP/PE at this dose and schedule has no activity in metastatic soft tissue sarcoma.
Affiliation:
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
Citation:
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. 1994, 30A (6):842-3 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
1994
URI:
http://hdl.handle.net/10541/97145
DOI:
10.1016/0959-8049(94)90303-4
PubMed ID:
7917546
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorVerweij, Jen
dc.contributor.authorJudson, Ien
dc.contributor.authorSteward, William Pen
dc.contributor.authorColeman, Ren
dc.contributor.authorWoll, Penella Jen
dc.contributor.authorVan Pottelsberghe, Cen
dc.contributor.authorVan Glabbeke, Martine Men
dc.contributor.authorMouridsen, Hen
dc.date.accessioned2010-04-22T10:51:29Z-
dc.date.available2010-04-22T10:51:29Z-
dc.date.issued1994-
dc.identifier.citationPhase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. 1994, 30A (6):842-3 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid7917546-
dc.identifier.doi10.1016/0959-8049(94)90303-4-
dc.identifier.urihttp://hdl.handle.net/10541/97145-
dc.description.abstractThe EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with intravenous muramyl tripeptide phosphatidylethanolamine (MTP/PE) at a dose of 4 mg once weekly in 20 patients with metastatic soft tissue sarcomas. Responses were not seen in 19 evaluable patients. Toxicity consisted mainly of a mild flu-like syndrome after 62% of drug administrations. It is concluded that MTP/PE at this dose and schedule has no activity in metastatic soft tissue sarcoma.en
dc.language.isoenen
dc.subjectSoft Tissue Canceren
dc.subject.meshAcetylmuramyl-Alanyl-Isoglutamine-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshDrug Carriers-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLiposomes-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPhosphatidylethanolamines-
dc.subject.meshSarcoma-
dc.subject.meshSoft Tissue Neoplasms-
dc.titlePhase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.